[
  {
    "ts": null,
    "headline": "Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients",
    "summary": "Edwards Lifesciences (NYSE:EW) recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone, coupled with robust Q1 earnings and updated financial guidance, likely bolstered investors' confidence, contributing to a 5% share price increase over the past month. The company’s advancements align with broader market trends, marked by a 2% rise, driven by strong earnings and positive economic...",
    "url": "https://finnhub.io/api/news?id=bbe664ba2636f2a28131ea5dc5adb468ca88f80a7887e1ad6c10064d49098ae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746208621,
      "headline": "Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients",
      "id": 134204684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences (NYSE:EW) recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone, coupled with robust Q1 earnings and updated financial guidance, likely bolstered investors' confidence, contributing to a 5% share price increase over the past month. The company’s advancements align with broader market trends, marked by a 2% rise, driven by strong earnings and positive economic...",
      "url": "https://finnhub.io/api/news?id=bbe664ba2636f2a28131ea5dc5adb468ca88f80a7887e1ad6c10064d49098ae1"
    }
  }
]